Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands		Total		Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Non-controlling Interests
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024		$ 1,158
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,350)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2025		(192)
Balance, beginning of period at Dec. 31, 2024		1,521,199		$ 1,428	$ 754,415	$ 9,737	$ 365,796	$ 389,823
Balance, beginning of period (in shares) at Dec. 31, 2024				142,747,818
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		41,383					41,383
Net income attributable to noncontrolling interests		18,932						18,932
Other comprehensive income		(5,809)				(5,809)
Distributions to noncontrolling interests		(19,239)						(19,239)
Vesting of restricted stock unit awards (in shares)				289,946
Vesting of restricted stock unit awards		(1,061)		$ 2	(1,063)
Equity-based compensation		9,263			9,263
Balance, ending of period at Mar. 31, 2025		1,564,668		$ 1,430	762,615	3,928	407,179	389,516
Balance, ending of period (in shares) at Mar. 31, 2025				143,037,764
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2024		1,158
Redeemable noncontrolling interests, ending balance at Sep. 30, 2025		(1,489)
Balance, beginning of period at Dec. 31, 2024		1,521,199		$ 1,428	754,415	9,737	365,796	389,823
Balance, beginning of period (in shares) at Dec. 31, 2024				142,747,818
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		90,855
Other comprehensive income		(12,371)
Balance, ending of period at Sep. 30, 2025		1,633,336		$ 1,432	782,765	(2,634)	456,651	395,122
Balance, ending of period (in shares) at Sep. 30, 2025				143,169,831
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2025		(192)
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(1,559)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2025		(1,751)
Balance, beginning of period at Mar. 31, 2025		1,564,668		$ 1,430	762,615	3,928	407,179	389,516
Balance, beginning of period (in shares) at Mar. 31, 2025				143,037,764
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		72,950					72,950
Net income attributable to noncontrolling interests		24,310						24,310
Other comprehensive income		(4,324)				(4,324)
Distributions to noncontrolling interests		(20,286)						(20,286)
Issuance of common stock (in shares)				7,553
Vesting of restricted stock unit awards (in shares)				66,306
Vesting of restricted stock unit awards		(438)		$ 1	(439)
Forfeitures of restricted stock awards (in shares)				(13,117)
Equity-based compensation		11,246			11,246
Balance, ending of period at Jun. 30, 2025		1,648,126		$ 1,431	773,422	(396)	480,129	393,540
Balance, ending of period (in shares) at Jun. 30, 2025				143,098,506
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		262
Redeemable noncontrolling interests, ending balance at Sep. 30, 2025		(1,489)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		(23,478)					(23,478)
Net income attributable to noncontrolling interests		24,423						24,423
Other comprehensive income		(2,238)				(2,238)
Distributions to noncontrolling interests		(22,841)						(22,841)
Vesting of restricted stock unit awards (in shares)				91,710
Vesting of restricted stock unit awards		(330)		$ 1	(331)
Forfeitures of restricted stock awards (in shares)				(20,385)
Equity-based compensation		9,674			9,674
Balance, ending of period at Sep. 30, 2025		1,633,336		$ 1,432	782,765	(2,634)	456,651	395,122
Balance, ending of period (in shares) at Sep. 30, 2025				143,169,831
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2025	[1]	(1,250)
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(2,513)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2026		(3,763)
Balance, beginning of period at Dec. 31, 2025		$ 1,686,214	[1]	$ 1,429	788,472	(3,610)	501,607	398,316
Balance, beginning of period (in shares) at Dec. 31, 2025		142,864,171		142,864,171
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		$ 39,850					39,850
Net income attributable to noncontrolling interests		21,151						21,151
Other comprehensive income		1,164				1,164
Distributions to noncontrolling interests		(21,314)						(21,314)
Vesting of restricted stock unit awards (in shares)				275,928
Vesting of restricted stock unit awards		(1,014)		$ 2	(1,016)
Forfeitures of restricted stock awards (in shares)				(6,274)
Equity-based compensation		8,929			8,929
Balance, ending of period at Mar. 31, 2026		1,734,980		$ 1,431	796,385	(2,446)	541,457	398,153
Balance, ending of period (in shares) at Mar. 31, 2026				143,133,825
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2025	[1]	(1,250)
Redeemable noncontrolling interests, ending balance at Sep. 30, 2026	[1]	(7,326)
Balance, beginning of period at Dec. 31, 2025		$ 1,686,214	[1]	$ 1,429	788,472	(3,610)	501,607	398,316
Balance, beginning of period (in shares) at Dec. 31, 2025		142,864,171		142,864,171
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		$ 101,265
Other comprehensive income		9,066
Balance, ending of period at Sep. 30, 2026		$ 1,789,009	[1]	$ 1,409	786,447	5,456	602,872	392,825
Balance, ending of period (in shares) at Sep. 30, 2026		140,931,614		140,931,614
Redeemable noncontrolling interests, beginning balance at Mar. 31, 2026		$ (3,763)
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(895)
Redeemable noncontrolling interests, ending balance at Jun. 30, 2026		(4,658)
Balance, beginning of period at Mar. 31, 2026		1,734,980		$ 1,431	796,385	(2,446)	541,457	398,153
Balance, beginning of period (in shares) at Mar. 31, 2026				143,133,825
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		16,899					16,899
Net income attributable to noncontrolling interests		18,685						18,685
Other comprehensive income		1,808				1,808
Proceeds from the sale of noncontrolling interest		2,723			1,218			1,505
Distributions to noncontrolling interests		(22,829)						(22,829)
Repurchase of common stock (in shares)				(1,397,765)
Repurchase of common stock		(13,160)		$ (14)	(13,146)
Vesting of restricted stock unit awards (in shares)				640,199
Vesting of restricted stock unit awards		(991)		$ 7	(998)
Forfeitures of restricted stock awards (in shares)				(465,361)
Forfeiture of restricted stock awards		(5)		$ (5)
Equity-based compensation		7,952			7,952
Balance, ending of period at Jun. 30, 2026		1,746,062		$ 1,419	791,411	(638)	558,356	395,514
Balance, ending of period (in shares) at Jun. 30, 2026				141,910,898
Increase (Decrease) in Temporary Equity [Roll Forward]
Net loss attributable to redeemable noncontrolling interests		(2,668)
Redeemable noncontrolling interests, ending balance at Sep. 30, 2026	[1]	(7,326)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss) attributable to Ardent Health Inc.		44,516					44,516
Net income attributable to noncontrolling interests		21,539						21,539
Other comprehensive income		6,094				6,094
Distributions to noncontrolling interests		(24,228)						(24,228)
Repurchase of common stock (in shares)				(1,039,500)
Repurchase of common stock		(11,090)		$ (10)	(11,080)
Vesting of restricted stock unit awards (in shares)				62,915
Vesting of restricted stock unit awards		(1,196)		$ 1	(1,197)
Forfeitures of restricted stock awards (in shares)				(2,699)
Forfeiture of restricted stock awards		(1)		$ (1)
Equity-based compensation		7,313			7,313
Balance, ending of period at Sep. 30, 2026		$ 1,789,009	[1]	$ 1,409	$ 786,447	$ 5,456	$ 602,872	$ 392,825
Balance, ending of period (in shares) at Sep. 30, 2026		140,931,614		140,931,614

[1] As of September 30, 2026 and December 31, 2025, the unaudited condensed consolidated balance sheets included total liabilities of consolidated variable interest entities of $301.7 million and $335.1 million, respectively. Refer to Note 2, Summary of Significant Accounting Policies, for further discussion.